Item 8.01. Other Events On February 9, 2023, Immunic, Inc. (the “Company”) issued a press release and presentation announcing a virtual celiac disease R&D webcast to highlight the current pathways for drug development, the current and potential treatment options and the unmet medical need for effective therapeutics. The company announced that initial results from the Part C portion of the ongoing phase 1 clinical trial of IMU-856 in celiac disease patients are expected to be available in mid-2023. The press release and presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. Item 9.01. Financial Statements and Exhibits E(…)
The Latest Press Releases